Table 2.
Elasticity results by molecule name
| Molecule name | Therapeutic category | Country | Elasticity | Brand pack price ($US) | Generic pack price ($US) | Pack size |
|---|---|---|---|---|---|---|
| Aciclovir | Antiviral | Kazakhstan | -1.3 | 17.5 | 3.9 | 25 |
| Aciclovir | Antiviral | Tunisia | -1.1 | 25.0 | 2.4 | 25 |
| Aciclovir | Antiviral | Philippines | -1.1 | 32.8 | 2.4 | 25 |
| Aciclovir | Antiviral | Syria | -1.3 | 21.8 | 5.0 | 25 |
| Amitriptyline | Antidepressant | Jordan | -1.4 | 2.6 | 0.8 | 100 |
| Amitriptyline | Antidepressant | Morocco | -1.2 | 5.1 | 0.8 | 100 |
| Amitriptyline | Antidepressant | Lebanon | -1.3 | 3.4 | 0.7 | 100 |
| Amlodipine | Calcium channel blocker | Malaysia | -1.1 | 8.8 | 0.4 | 30 |
| Atenolol | Antihypertensive | Syria | -1.4 | 5.9 | 1.7 | 60 |
| Atenolol | Antihypertensive | Philippines | -1.0 | 7.4 | 0.3 | 28 |
| Beclometasone | Asthma | Peru | -2.0 | 6.8 | 3.4 | 200 |
| Beclometasone | Asthma | Morocco | -1.5 | 7.9 | 2.5 | 200 |
| Benzathine benzylpenicillin | Antibiotic | Morocco | -1.4 | 2.2 | 0.6 | 4 |
| Captopril | Antihypertensive | Morocco | -1.5 | 59.6 | 20.3 | 60 |
| Captopril | Antihypertensive | Malaysia | -1.7 | 3.9 | 1.6 | 60 |
| Captopril | Antihypertensive | Kazakhstan | -1.4 | 5.1 | 1.6 | 60 |
| Captopril | Antihypertensive | Pakistan | -1.1 | 5.6 | 0.5 | 60 |
| Captopril | Antihypertensive | Philippines | -1.1 | 56.2 | 4.0 | 150 |
| Carbamazepine | Epilepsy | Kazakhstan | -1.8 | 26.9 | 12.2 | 150 |
| Carbamazepine | Epilepsy | Shanghai | -1.2 | 13.1 | 2.0 | 100 |
| Carbamazepine | Epilepsy | Shandong | -1.2 | 12.5 | 2.0 | 100 |
| Carbamazepine | Epilepsy | Philippines | -1.1 | 115.1 | 10.0 | 500 |
| Carbamazepine | Epilepsy | Kuwait | -1.3 | 12.2 | 2.9 | 150 |
| Carbamazepine | Epilepsy | Malaysia | -1.5 | 6.4 | 2.0 | 100 |
| Carbamazepine | Epilepsy | Syria | -1.4 | 20.2 | 5.5 | 150 |
| Ceftriaxone | Antibiotic | South Africa | -1.2 | 8.5 | 1.5 | 1 |
| Ceftriaxone | Antibiotic | Malaysia | -1.7 | 6.1 | 2.6 | 1 |
| Ceftriaxone | Antibiotic | Kazakhstan | -1.4 | 10.4 | 3.0 | 1 |
| Ceftriaxone | Antibiotic | Philippines | -1.4 | 9.1 | 2.6 | 1 |
| Ceftriaxone | Antibiotic | Shanghai | -1.1 | 10.2 | 0.7 | 1 |
| Ceftriaxone | Antibiotic | Shandong | -1.0 | 12.5 | 0.4 | 1 |
| Ciprofloxacin | Antibiotic | Kazakhstan | -1.2 | 0.2 | 0.0 | 1 |
| Ciprofloxacin | Antibiotic | Nigeria | -1.3 | 0.9 | 0.2 | 1 |
| Ciprofloxacin | Antibiotic | Morocco | -1.6 | 2.1 | 0.8 | 1 |
| Ciprofloxacin | Antibiotic | Philippines | -1.0 | 111.0 | 3.2 | 100 |
| Ciprofloxacin | Antibiotic | South Africa | -1.1 | 0.7 | 0.0 | 1 |
| Co-trimoxazole | Antibiotic | Syria | -1.5 | 0.8 | 0.3 | 70 |
| Co-trimoxazole | Antibiotic | Tunisia | -1.2 | 1.9 | 0.3 | 70 |
| Diazepam | Anxiolytic | Tunisia | -1.8 | 2.8 | 1.3 | 100 |
| Diazepam | Anxiolytic | Jordan | -1.7 | 0.9 | 0.4 | 100 |
| Diazepam | Anxiolytic | Syria | -1.4 | 3.9 | 1.2 | 100 |
| Diazepam | Anxiolytic | Morocco | -1.1 | 3.8 | 0.4 | 100 |
| Diclofenac | Anti-inflammatory | Shandong | -1.7 | 9.3 | 4.0 | 100 |
| Diclofenac | Anti-inflammatory | Syria | -1.3 | 9.3 | 1.9 | 100 |
| Diclofenac | Anti-inflammatory | Philippines | -1.0 | 15.6 | 0.5 | 100 |
| Diclofenac | Anti-inflammatory | Kazakhstan | -1.1 | 27.1 | 2.1 | 100 |
| Diclofenac | Anti-inflammatory | Morocco | -1.1 | 9.7 | 0.5 | 100 |
| Digoxin | Cardio therapy | Philippines | -1.1 | 28.5 | 3.3 | 500 |
| Fluconazole | Antifungal | South Africa | -1.1 | 107.7 | 12.3 | 30 |
| Fluconazole | Antifungal | Tunisia | -1.0 | 325.9 | 3.6 | 30 |
| Fluconazole | Antifungal | Jordan | -1.8 | 0.2 | 0.1 | 1 |
| Fluoxetine | Antidepressant | Malaysia | -1.0 | 27.5 | 0.9 | 30 |
| Fluoxetine | Antidepressant | Shandong | -1.4 | 34.6 | 10.5 | 30 |
| Fluoxetine | Antidepressant | Shanghai | -1.7 | 35.1 | 14.3 | 30 |
| Fluoxetine | Antidepressant | Philippines | -1.0 | 49.7 | 0.8 | 28 |
| Fluphenazine | Antipsychotic | Morocco | -1.4 | 1.8 | 0.5 | 1 |
| Fluphenazine | Antipsychotic | Jordan | -2.0 | 1.0 | 0.5 | 1 |
| Furosemide | Diueretic | Philippines | -1.0 | 3.5 | 0.1 | 28 |
| Furosemide | Diueretic | Jordan | -2.0 | 0.2 | 0.1 | 20 |
| Glibenclamide | Diabetes | Philippines | -1.1 | 14.6 | 0.8 | 200 |
| Indinavir | Antiviral | Morocco | -1.9 | 133.4 | 62.6 | 180 |
| Loratadine | Antihistamine | Syria | -1.3 | 4.2 | 1.0 | 20 |
| Loratadine | Antihistamine | Malaysia | -1.1 | 2.4 | 0.2 | 10 |
| Mebendazole | Antiparasitic | Kazakhstan | -1.0 | 1.3 | 0.0 | 6 |
| Mebendazole | Antiparasitic | Kyrgyzstan | -1.0 | 1.5 | 0.0 | 6 |
| Medroxyprogesterone | Contraceptive | Kazakhstan | -1.2 | 7.4 | 1.0 | 1 |
| Metformin | Diabetes | Nigeria | -1.2 | 7.1 | 1.4 | 100 |
| Metformin | Diabetes | Pakistan | -1.6 | 1.7 | 0.7 | 100 |
| Metformin | Diabetes | Shanghai | -1.2 | 15.3 | 2.8 | 100 |
| Metformin | Diabetes | Philippines | -1.2 | 11.0 | 1.8 | 100 |
| Metronidazole | Antiparasitic | Syria | -1.9 | 0.8 | 0.4 | 20 |
| Metronidazole | Antiparasitic | Philippines | -1.0 | 24.5 | 0.4 | 100 |
| Nevirapine | Antiviral | Lebanon | -1.2 | 197.8 | 31.0 | 60 |
| Nevirapine | Antiviral | Morocco | -1.2 | 72.3 | 14.1 | 60 |
| Nifedipine Retard | Anti hypertensive | Morocco | -1.1 | 41.2 | 2.2 | 100 |
| Nifedipine Retard | Anti hypertensive | Kuwait | -1.3 | 11.9 | 2.4 | 100 |
| Omeprazole | Antacid | Shandong | -1.1 | 39.1 | 3.6 | 30 |
| Omeprazole | Antacid | Shanghai | -1.3 | 39.2 | 8.5 | 30 |
| Paracetamol | Anti-inflammatory | Syria | -1.3 | 1.1 | 0.2 | 20 |
| Phenytoin | Epilepsy | Lebanon | -1.2 | 4.1 | 0.7 | 100 |
| Phenytoin | Epilepsy | Kuwait | -1.2 | 3.7 | 0.7 | 100 |
| Phenytoin | Epilepsy | Jordan | -1.2 | 4.6 | 0.7 | 100 |
| Phenytoin | Epilepsy | Tunisia | -1.3 | 3.2 | 0.7 | 100 |
| Ranitidine | Antacid | Philippines | -1.1 | 23.0 | 1.2 | 50 |
| Ranitidine | Antacid | Kazakhstan | -1.1 | 11.7 | 1.5 | 60 |
| Ranitidine | Antacid | Syria | -1.3 | 9.5 | 2.4 | 60 |
| Simvastatin | Lipid lowering | Malaysia | -1.1 | 104.2 | 10.0 | 120 |
| Streptomycin | Antibiotic | Morocco | -1.4 | 0.4 | 0.1 | 1 |
| Zidovudine | Antiviral | Lebanon | -1.1 | 296.0 | 18.6 | 150 |
| Zidovudine | Antiviral | Malaysia | -1.9 | 78.8 | 37.5 | 100 |
Source: WHO/HAI 2006.